Trial Profile
A study to evaluate renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy inantiretroviral-naive patients .
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Oct 2015
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Efavirenz; Lopinavir/ritonavir; Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms TRIP
- 16 Oct 2015 New trial record